help poor countries essay how do i start my scholarship essay doctorate with the thesis subject pollution business plan free template word i need a 3 page essay online dissertation help verlag discussion dissertation qualitative computer engineering resume cover letter 3l writing a cover letter with cv buy homework answers
Skip to main content

Treating Alzheimer´s disease by targeting Amyloid ß-nitration

Ref-Nr: TA-2311


Kurzfassung

A novel therapeutic/diagnostic/ prophylactic approach


Hintergrund

Part of the inflammatory response in Alzheimer´s disease (AD) is the upregulation of the inducible nitric oxide synthase NOS2 resulting in increased NO production. NO contributes to cell signaling by inducing posttranslational protein modifications. Under pathological conditions there is a shift to the formation of protein tyrosine nitration by secondary products like peroxynitrite and nitrogen dioxide.


Lösung

The invention is based on the finding that amyloid β (Aβ) is nitrated at tyrosine 10 in AD-brains. Nitration accelerates its aggregation and is present in Aβ plaques. Injection of the nitrated protein into the brain of APP/PS1 transgenic mice leads to β-amyloidosis.

An antibody specific to the nitrated form of Aβ has been developed. A therapeutic approach interfering with the nitrated Aβ (rather than with the native Aβ-peptide) may provide a very specific treatment with a reduced risk of side-effects.


Vorteile

  • Specific early diagnosis of AD
  • Novel and specific approach for treating AD
  • Antibody specific to nitrated Aβ for further clinical development

Anwendungsbereiche

The invention offers a novel approach for an early diagnosis of AD. The invention also opens new avenues for developing either NCEs or biologicals interfering with the nitrated Aβ. Antibody-based therapeutic approaches (e.g. passive/active vaccination) are currently been developed. Prophylactic approaches are also conceivable.


Service

On behalf of University of Bonn, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development.


PROvendis GmbH

Dr. Jürgen Walkenhorst
+49.208 94105-25
jw@provendis.info
www.provendis.info
Adresse
Schloßstr. 11-15
45468 Mülheim an der Ruhr



Entwicklungsstand

Funktionsnachweis


Stichworte

Treating Alzheimer´s disease by targeting Amyloid ß-nitration - A novel therapeutic/diagnostic/ prophylactic approach

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsführerin)

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen